GLP-1 Receptor Agonist Market Growth, Size, Trends Analysis- By Product, By Application, By Route of Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

GLP-1 Receptor Agonist Market Introduction and Overview

According to SPER Market Research, 'Global GLP-1 Receptor Agonist Market Size- By Product, By Application, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' states that the Global GLP-1 Receptor Agonist Market is estimated to reach USD 266.54 billion by 2033 with a CAGR of 21.9%.

GLP-1 receptor agonists are a type of medication primarily prescribed for managing type 2 diabetes and have recently gained attention for their effectiveness in treating obesity. They function similarly to glucagon-like peptide-1 (GLP-1), a hormone that increases insulin production, delays stomach emptying, decreases glucagon release, and encourages feelings of fullness in response to meals.

The global market for GLP-1 receptor agonists was significantly impacted by the COVID-19 epidemic in a variety of ways. Initially, health care disruption resulted in fewer visits to patients and delayed identification of diabetes and obesity, which in turn led to fewer new prescriptions for these drugs. GLP-1 receptor agonist availability was also impacted by supply chain disruptions, leading to shortages in some areas.

Scope of the report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Product, By Application, By Route of Administration, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi.

GLP-1 Receptor Agonist Market Segmentation:

By Product: Based on the Product, Global GLP-1 Receptor Agonist Market is segmented as; Ozempic,k Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other.

By Route of Administration: Based on the Route of Administration, Global GLP-1 Receptor Agonist Market is segmented as; Parenteral, Oral.

By Distribution Channel: Based on the Distribution Channel, Global GLP-1 Receptor Agonist Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.

Product Code: PHAR2415

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global GLP-1 Receptor Agonist Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global GLP-1 Receptor Agonist Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global GLP-1 Receptor Agonist Market

7. Global GLP-1 Receptor Agonist Market, By Product (USD Million) 2020-2033

7.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Product, 2020-2026
7.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Product, 2027-2033
7.3. Ozempic
7.4. Trulicity
7.5. Mounjaro
7.6. Wegovy
7.7. Rybelsus
7.8. Saxenda
7.9. Victoza
7.10. Zepbound
7.11. Other Products

8. Global GLP-1 Receptor Agonist Market, By Application (USD Million) 2020-2033

8.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Application, 2020-2026
8.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Application, 2027-2033
8.3. Type 2 Diabetes Mellitus
8.4. Obesity

9. Global GLP-1 Receptor Agonist Market, By Route of Administration (USD Million) 2020-2033

9.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Route of Administration, 2020-2026
9.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Route of Administration, 2027-2033
9.3. Parenteral
9.4. Oral

10. Global GLP-1 Receptor Agonist Market, By Distribution Channel (USD Million) 2020-2033

10.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Distribution Channel, 2020-2026
10.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Distribution Channel, 2027-2033
10.3. Hospital Pharmacies
10.4. Retail Pharmacies
10.5. Online Pharmacies

11. Global GLP-1 Receptor Agonist Market Forecast, 2020-2033 (USD Million)

11.1. Global GLP-1 Receptor Agonist Market Size and Market Share

12. Global GLP-1 Receptor Agonist Market, By Region, 2020-2033 (USD Million)

12.1. Global GLP-1 Receptor Agonist Market Size and Market Share By Region (2020-2026)
12.2. Global GLP-1 Receptor Agonist Market Size and Market Share By Region (2027-2033)
12.3. Asia-Pacific
- 12.3.1. Australia
- 12.3.2. China
- 12.3.3. India
- 12.3.4. Japan
- 12.3.5. South Korea
- 12.3.6. Rest of Asia-Pacific
12.4. Europe
- 12.4.1. France
- 12.4.2. Germany
- 12.4.3. Italy
- 12.4.4. Spain
- 12.4.5. United Kingdom
- 12.4.6. Rest of Europe
12.5. Middle East and Africa
- 12.5.1. Kingdom of Saudi Arabia
- 12.5.2. United Arab Emirates
- 12.5.3. Qatar
- 12.5.4. South Africa
- 12.5.5. Egypt
- 12.5.6. Morocco
- 12.5.7. Nigeria
- 12.5.8. Rest of Middle-East and Africa
12.6. North America
- 12.6.1. Canada
- 12.6.2. Mexico
- 12.6.3. United States
12.7. Latin America
- 12.7.1. Argentina
- 12.7.2. Brazil
- 12.7.3. Rest of Latin America

13. Company Profile

13.1. Eli Lilly and Company
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Sanofi
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Novo Nordisk A/S
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. AstraZeneca
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Others